A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
PURPOSE: The number of older adults with head and neck squamous cell carcinoma (HNSCC) is increasing, and treatment of these patients is challenging. Although cisplatin-based chemotherapy concomitantly with radiation therapy is considered the standard regimen for patients with locoregionally advanced HNSCC, there is substantial real-world heterogeneity regarding concomitant chemotherapy in older patients with HNSCC.
METHODS AND MATERIALS: The SENIOR study is an international multicenter cohort study including older patients (≥65 years) with HNSCC treated with definitive radiation therapy at 13 academic centers in the United States and Europe. Patients with concomitant chemoradiation were analyzed regarding overall survival (OS) and progression-free survival (PFS) via Kaplan-Meier analyses. Fine-Gray competing risk regressions were performed regarding the incidence of locoregional failures and distant metastases.
RESULTS: Six hundred ninety-seven patients with a median age of 71 years were included in this analysis. Single-agent cisplatin was the most common chemotherapy regimen (n = 310; 44%), followed by cisplatin plus 5-fluorouracil (n = 137; 20%), carboplatin (n = 73; 10%), and mitomycin C plus 5-fluorouracil (n = 64; 9%). Carboplatin-based regimens were associated with diminished PFS (hazard ratio [HR], 1.39 [1.03-1.89]; P < .05) and a higher incidence of locoregional failures (subdistribution HR, 1.54 [1.00-2.38]; P = .05) compared with single-agent cisplatin, whereas OS (HR, 1.15 [0.80-1.65]; P = .46) was comparable. There were no oncological differences between single-agent and multiagent cisplatin regimens (all P > .05). The median cumulative dose of cisplatin was 180 mg/m2 (IQR, 120-200 mg/m2). Cumulative cisplatin doses ≥200 mg/m2 were associated with increased OS (HR, 0.71 [0.53-0.95]; P = .02), increased PFS (HR, 0.66 [0.51-0.87]; P = .003), and lower incidence of locoregional failures (subdistribution HR, 0.50 [0.31-0.80]; P = .004). Higher cumulative cisplatin doses remained an independent prognostic variable in the multivariate regression analysis for OS (HR, 0.996 [0.993-0.999]; P = .009).
CONCLUSIONS: Single-agent cisplatin can be considered in the standard chemotherapy regimen for older patients with HNSCC who can tolerate cisplatin. Cumulative cisplatin doses are prognostically relevant in older patients with HNSCC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
---|---|
Enthalten in: |
International journal of radiation oncology, biology, physics - 118(2024), 5 vom: 01. März, Seite 1282-1293 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
BG3F62OND5 |
---|
Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ijrobp.2023.10.025 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM364060395 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM364060395 | ||
003 | DE-627 | ||
005 | 20240318233758.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ijrobp.2023.10.025 |2 doi | |
028 | 5 | 2 | |a pubmed24n1334.xml |
035 | |a (DE-627)NLM364060395 | ||
035 | |a (NLM)37914144 | ||
035 | |a (PII)S0360-3016(23)08025-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rühle, Alexander |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.03.2024 | ||
500 | |a Date Revised 18.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
520 | |a PURPOSE: The number of older adults with head and neck squamous cell carcinoma (HNSCC) is increasing, and treatment of these patients is challenging. Although cisplatin-based chemotherapy concomitantly with radiation therapy is considered the standard regimen for patients with locoregionally advanced HNSCC, there is substantial real-world heterogeneity regarding concomitant chemotherapy in older patients with HNSCC | ||
520 | |a METHODS AND MATERIALS: The SENIOR study is an international multicenter cohort study including older patients (≥65 years) with HNSCC treated with definitive radiation therapy at 13 academic centers in the United States and Europe. Patients with concomitant chemoradiation were analyzed regarding overall survival (OS) and progression-free survival (PFS) via Kaplan-Meier analyses. Fine-Gray competing risk regressions were performed regarding the incidence of locoregional failures and distant metastases | ||
520 | |a RESULTS: Six hundred ninety-seven patients with a median age of 71 years were included in this analysis. Single-agent cisplatin was the most common chemotherapy regimen (n = 310; 44%), followed by cisplatin plus 5-fluorouracil (n = 137; 20%), carboplatin (n = 73; 10%), and mitomycin C plus 5-fluorouracil (n = 64; 9%). Carboplatin-based regimens were associated with diminished PFS (hazard ratio [HR], 1.39 [1.03-1.89]; P < .05) and a higher incidence of locoregional failures (subdistribution HR, 1.54 [1.00-2.38]; P = .05) compared with single-agent cisplatin, whereas OS (HR, 1.15 [0.80-1.65]; P = .46) was comparable. There were no oncological differences between single-agent and multiagent cisplatin regimens (all P > .05). The median cumulative dose of cisplatin was 180 mg/m2 (IQR, 120-200 mg/m2). Cumulative cisplatin doses ≥200 mg/m2 were associated with increased OS (HR, 0.71 [0.53-0.95]; P = .02), increased PFS (HR, 0.66 [0.51-0.87]; P = .003), and lower incidence of locoregional failures (subdistribution HR, 0.50 [0.31-0.80]; P = .004). Higher cumulative cisplatin doses remained an independent prognostic variable in the multivariate regression analysis for OS (HR, 0.996 [0.993-0.999]; P = .009) | ||
520 | |a CONCLUSIONS: Single-agent cisplatin can be considered in the standard chemotherapy regimen for older patients with HNSCC who can tolerate cisplatin. Cumulative cisplatin doses are prognostically relevant in older patients with HNSCC | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Cisplatin |2 NLM | |
650 | 7 | |a Q20Q21Q62J |2 NLM | |
650 | 7 | |a Carboplatin |2 NLM | |
650 | 7 | |a BG3F62OND5 |2 NLM | |
650 | 7 | |a Fluorouracil |2 NLM | |
650 | 7 | |a U3P01618RT |2 NLM | |
700 | 1 | |a Weymann, Maria |e verfasserin |4 aut | |
700 | 1 | |a Behrens, Max |e verfasserin |4 aut | |
700 | 1 | |a Marschner, Sebastian |e verfasserin |4 aut | |
700 | 1 | |a Haderlein, Marlen |e verfasserin |4 aut | |
700 | 1 | |a Fabian, Alexander |e verfasserin |4 aut | |
700 | 1 | |a Senger, Carolin |e verfasserin |4 aut | |
700 | 1 | |a Dickstein, Daniel R |e verfasserin |4 aut | |
700 | 1 | |a Kraft, Johannes |e verfasserin |4 aut | |
700 | 1 | |a von der Grün, Jens |e verfasserin |4 aut | |
700 | 1 | |a Chen, Eric |e verfasserin |4 aut | |
700 | 1 | |a Aquino-Michaels, Todd |e verfasserin |4 aut | |
700 | 1 | |a Domschikowski, Justus |e verfasserin |4 aut | |
700 | 1 | |a Bickel, Amanda |e verfasserin |4 aut | |
700 | 1 | |a Altay-Langguth, Alev |e verfasserin |4 aut | |
700 | 1 | |a Kalinauskaite, Goda |e verfasserin |4 aut | |
700 | 1 | |a Lewitzki, Victor |e verfasserin |4 aut | |
700 | 1 | |a Bonomi, Marcelo |e verfasserin |4 aut | |
700 | 1 | |a Blakaj, Dukagjin M |e verfasserin |4 aut | |
700 | 1 | |a Jhawar, Sachin R |e verfasserin |4 aut | |
700 | 1 | |a Baliga, Sujith |e verfasserin |4 aut | |
700 | 1 | |a Barve, Rahul |e verfasserin |4 aut | |
700 | 1 | |a Ferentinos, Konstantinos |e verfasserin |4 aut | |
700 | 1 | |a Zamboglou, Constantinos |e verfasserin |4 aut | |
700 | 1 | |a Schnellhardt, Sören |e verfasserin |4 aut | |
700 | 1 | |a Haehl, Erik |e verfasserin |4 aut | |
700 | 1 | |a Spohn, Simon K B |e verfasserin |4 aut | |
700 | 1 | |a Kuhnt, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Zöller, Daniela |e verfasserin |4 aut | |
700 | 1 | |a Guckenberger, Matthias |e verfasserin |4 aut | |
700 | 1 | |a Budach, Volker |e verfasserin |4 aut | |
700 | 1 | |a Belka, Claus |e verfasserin |4 aut | |
700 | 1 | |a Bakst, Richard |e verfasserin |4 aut | |
700 | 1 | |a Mayer, Arnulf |e verfasserin |4 aut | |
700 | 1 | |a Schmidberger, Heinz |e verfasserin |4 aut | |
700 | 1 | |a Grosu, Anca-Ligia |e verfasserin |4 aut | |
700 | 1 | |a Balermpas, Panagiotis |e verfasserin |4 aut | |
700 | 1 | |a Stromberger, Carmen |e verfasserin |4 aut | |
700 | 1 | |a Nicolay, Nils H |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of radiation oncology, biology, physics |d 1976 |g 118(2024), 5 vom: 01. März, Seite 1282-1293 |w (DE-627)NLM000375381 |x 1879-355X |7 nnns |
773 | 1 | 8 | |g volume:118 |g year:2024 |g number:5 |g day:01 |g month:03 |g pages:1282-1293 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijrobp.2023.10.025 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 118 |j 2024 |e 5 |b 01 |c 03 |h 1282-1293 |